Agios Pharmaceuticals, Inc. financial data

Symbol
AGIO on Nasdaq
Industry
Pharmaceutical Preparations
Location
88 Sidney Street, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.18K % -19.5%
Quick Ratio 34.6 % +84.1%
Debt-to-equity 15 % +23.5%
Return On Equity -47.1 % -133%
Return On Assets -40.9 % -127%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 56.9M shares +2.07%
Common Stock, Shares, Outstanding 56.9M shares +2.05%
Entity Public Float 1.56B USD +29.8%
Common Stock, Value, Issued 71K USD +1.43%
Weighted Average Number of Shares Outstanding, Basic 56.8M shares +2.16%
Weighted Average Number of Shares Outstanding, Diluted 56.8M shares +2.16%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 31.3M USD +55.4%
Research and Development Expense 305M USD +12.5%
General and Administrative Expense 29.1M USD +7.26%
Costs and Expenses 436M USD +10.6%
Operating Income (Loss) -405M USD -8.14%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -365M USD -73.7%
Earnings Per Share, Basic -6.49 USD/shares -71.2%
Earnings Per Share, Diluted -6.49 USD/shares -71.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 84.5M USD -0.28%
Cash, Cash Equivalents, and Short-term Investments 645M USD -31.9%
Inventory, Net 23.9M USD +52.7%
Assets, Current 632M USD -16.5%
Property, Plant and Equipment, Net 12.7M USD -35.2%
Operating Lease, Right-of-Use Asset 48.8M USD -18.6%
Other Assets, Noncurrent 4.06M USD -0.03%
Assets 773M USD -28.8%
Accounts Payable, Current 10M USD -13.7%
Employee-related Liabilities, Current 12M USD +9.93%
Accrued Liabilities, Current 36.7M USD +25.9%
Contract with Customer, Liability, Current 2.5M USD
Liabilities, Current 62.6M USD +13.6%
Operating Lease, Liability, Noncurrent 48.8M USD -24.5%
Other Liabilities, Noncurrent 1.16M USD 0%
Liabilities 113M USD -6.92%
Retained Earnings (Accumulated Deficit) -1B USD -57.4%
Stockholders' Equity Attributable to Parent 661M USD -31.5%
Liabilities and Equity 773M USD -28.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -99.9M USD -4.92%
Net Cash Provided by (Used in) Financing Activities 5.86M USD +138%
Net Cash Provided by (Used in) Investing Activities 125M USD +116%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 73.1M shares +1.59%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 30.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 84.5M USD -0.28%
Deferred Tax Assets, Valuation Allowance 380M USD +28.3%
Deferred Tax Assets, Gross 395M USD +25%
Operating Lease, Liability 64.6M USD -18.1%
Payments to Acquire Property, Plant, and Equipment 141K USD -64.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -357M USD -71.3%
Lessee, Operating Lease, Liability, to be Paid 71.7M USD -20.5%
Property, Plant and Equipment, Gross 67.6M USD -7.45%
Operating Lease, Liability, Current 15.9M USD +10.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20.2M USD +3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 19.5M USD +4.54%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.08M USD -36.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 20.8M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 64.1M USD +94.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25M shares 0%
Unrecognized Tax Benefits 28.6M USD +9.12%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.48M USD -83.2%
Operating Lease, Payments 18.4M USD +2.95%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 43.7M USD -1.82%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%